Wartość Rok IPO organizacji OncoSec Medical Inc to 2011
Pierwsza oferta publiczna jest rodzajem oferty publicznej, w której akcje spółki zazwyczaj sprzedawane są inwestorom instytucjonalnym, którzy z kolei sprzedają się ogółowi społeczeństwa, na giełdzie papierów wartościowych, po raz pierwszy.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar